RCM
VNDA icon

Rotella Capital Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Rotella Capital Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-109,800
Closed -$1.24M – 583
2015
Q3 		$1.24M Buy
+109,800
New +$1.34M 0.4% 114

Other funds holding VNDA

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Rotella Capital Management's VNDA Position: Q4 2015 in Review

Rotella Capital Management sold out of Vanda Pharmaceuticals (VNDA) in Q4 2015, closing a stake of 109,800 shares — an estimated $1.24M sold.

Rotella Capital Management first reported a position in VNDA in Q3 2015 and held it in 1 quarter. The position peaked at $1.24M in Q3 2015. 117 funds tracked by Wall St. Rank hold VNDA as of Q4 2015.

  • Rotella Capital Management reported no remaining Vanda Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Rotella Capital Management sold 109,800 Vanda Pharmaceuticals shares in Q4 2015, an estimated $1.24M.
  • Rotella Capital Management first reported a position in Vanda Pharmaceuticals in Q3 2015 and held it in 1 quarter.
  • Rotella Capital Management's Vanda Pharmaceuticals position peaked at $1.24M in Q3 2015.
  • 117 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2015.

Based on Rotella Capital Management's 13F filing for Q4 2015, filed 9 Feb 2016.